OSE Immunotherapeutics Clarifies Strategy Amid Shareholder Activism

OSE Immunotherapeutics has published a Shareholder Q&A to provide detailed insights into its strategic priorities and operations ahead of its Annual General Meeting (AGM) on September 30, 2025. The release comes amid rising shareholder activism and misinformation campaigns led by minority shareholders.

The company remains committed to advancing its flagship programs, Tedopi® and Lusvertikimab. Tedopi®, in a pivotal phase 3 trial for lung cancer, and Lusvertikimab, planned for a phase 2b trial in ulcerative colitis, are expected to progress through strategic partnerships and adequate financing. Meanwhile, OSE is combating misinformation and legal challenges regarding shareholder actions.

Future steps include the AGM on September 30, where shareholders will decide on strategic directions amidst ongoing legal proceedings. The company fosters open dialogue and transparency to counter misinformation and maintain shareholder trust.